ArticleHepatobiliary surgery and nutrition2020
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?
Article in Hepatobiliary surgery and nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma.Journal of cancer research and clinical oncology · 2023Trial
- Resected intrahepatic cholangiocarcinoma: Is adjuvant chemotherapy associated with improved overall survival?American journal of surgery · 2026Article
- Construction and validation of a novel prognostic model for postoperative patients with stage I intrahepatic cholangiocarcinoma: a population-based study.Langenbeck's archives of surgery · 2025Article
- The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2025Article
- Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.Cell death & disease · 2024Article
- The Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis.Journal of inflammation research · 2024Article
- Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma.Frontiers in pharmacology · 2024Review
- Role of routine lymph node dissection alongside resection of intrahepatic cholangiocarcinoma: Systematic review and meta-analysis.World journal of gastrointestinal oncology · 2023Article
- Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2023Article
- Characteristics and clinical outcomes in young-onset cholangiocarcinoma.Cancer medicine · 2023Article
- Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping.Cancers · 2022Article
- Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.Journal of clinical and translational hepatology · 2022Review
- Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study.BMC cancer · 2022Article
- Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus.Hepatobiliary surgery and nutrition · 2021Article
- Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives.Hepatobiliary surgery and nutrition · 2021Article
- Proposal of a New Definition of "Very Early" Intrahepatic Cholangiocarcinoma-A Retrospective Single-Center Analysis.Journal of clinical medicine · 2021Article
- Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data.Hepatobiliary surgery and nutrition · 2021Article
- Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study.Scientific reports · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is rare with limited evidence-based guidelines. This retrospective study evaluates the use of chemotherapy in patients with resected ICC.
methodsThe Surveillance Epidemiology and End Results (SEER) program database was used to identify patients with resected ICC. Patients were stratified by date of diagnosis (2000-2004, 2005-2009, 2010-2014), T, and N stage. Multivariable logistic regression models identified predictors of chemotherapy use. Kaplan-Meier and Cox proportional hazard models were used to identify survival trends.
resultsOne thousand and two hundred twenty-three patients met inclusion criteria. Chemotherapy utilization increased over time (33% to 41%, P≤0.05). Chemotherapy use increased in lymph node (LN) positive patients [32% to 60% in 2010-2014; (P≤0.05) and T3/T4 disease (40% to 60% in 2010-2014; P≤0.01], but not in patients with LN negative or T1/T2 disease. LN positivity was associated with utilization of chemotherapy in 2005-2009 and 2010-2014. Overall survival increased from 32 to 41 months (P≤0.05). In LN positive patients, chemotherapy was associated with a decreased hazard ratio of death (P≤0.05) and T3/T4 disease was associated with an increased hazard ratio of death (P≤0.05).
conclusionsAdjuvant chemotherapy use in ICC has increased. More LN positive or patients with T3/T4 tumors are receiving chemotherapy, which may explain the improvement in overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.